ArticleEuropean journal of nuclear medicine and molecular imaging2024
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Diagnostic value of dual-tracer PET/CT with [Frontiers in medicine · 2025Pooled it
- Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.European urology open science · 2026Article
- Potential value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative evaluation of [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT for lesion detection and uptake in prostate cancer across disease stages.EJNMMI research · 2026Article
- Advances in neurotensin receptor 1-targeted molecular probes for tumor molecular imaging and therapy.Frontiers in oncology · 2026Review
- Clinical and imaging manifestations of metastases from rare sites.Quantitative imaging in medicine and surgery · 2026Review
- Performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.Frontiers in oncology · 2026Article
- Multitracer comparison of gold standard PSMA-PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Global Challenges in the Provision of Theranostic Services the International Atomic Energy Agency (IAEA) Perspective.World journal of nuclear medicine · 2025Article
- An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy.Frontiers in oncology · 2025Review
- Dual targeting PET tracer [Theranostics · 2025Article
- CircRNAs and miRNAs: Key Player Duo in Breast Cancer Dynamics and Biomarkers for Breast Cancer Early Detection and Prevention.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [ MATERIAL AND
methodsPatients with advanced, progressive mCRPC underwent clinical [
resultsIn ten patients, 472 lesions were detected on all imaging modalities (miTNM regions: M1b: 327 (69.3%), M1a: 95 (20.1%), N1: 26 (5.5%), M1c: 18 (3.8%), T: 5 (1.1%) and Tr: 1 (0.2%). [
conclusionThrough whole-body imaging, we identify considerable inter- and intra-patient heterogeneity of mCRPC and potential imaging phenotypes. Regarding uptake and tumour detection, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.